EGFR and lung cancer: Do patients diagnosed with EGFR-mutant non–small cell lung cancer (NSCLC) receiving osimertinib have higher cancer therapy–related cardiac events (CTRCEs) compared with those receiving other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs)?